Abstract
ABSTRACT: Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.
Original language | English (US) |
---|---|
Pages (from-to) | 557-577 |
Number of pages | 21 |
Journal | Pancreas |
Volume | 42 |
Issue number | 4 |
DOIs | |
State | Published - May 2013 |
Keywords
- carcinoid
- neuroendocrine tumors
- neuroendocrine/diagnosis
- neuroendocrine/pathology
- neuroendocrine/treatment
- pheochromocytoma
ASJC Scopus subject areas
- Hepatology
- Internal Medicine
- Endocrinology
- Endocrinology, Diabetes and Metabolism